In today’s briefing:
- Aspira Women’s Health, Inc. – Provides Important Update on EndoCheck Diagnostic Test
- Culp, Inc. – Revising Estimates After 2QFY24 Positive Surprise
Aspira Women’s Health, Inc. – Provides Important Update on EndoCheck Diagnostic Test
- Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October.
- This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma.
- Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis.
Culp, Inc. – Revising Estimates After 2QFY24 Positive Surprise
- We are revising our earnings estimates following Culp’s 2QFY24 earnings release and conference call.
- Management’s 3QFY24 guidance suggests that our prior estimate was overly optimistic about the pace of improvement.
- The objective of operating profitability by 4Q remains intact and achievable. We expect, and are modeling, positive net income in FY25.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
